Načítá se...
Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy
With the rapid increase in cancer survival because of improved diagnosis and therapy in the past decades, cancer treatment–related cardiotoxicity is becoming an urgent healthcare concern. The anthracycline doxorubicin (DOX), one of the most effective chemotherapeutic agents to date, causes cardiomyo...
Uloženo v:
| Vydáno v: | J Biol Chem |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Biochemistry and Molecular Biology
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6314117/ https://ncbi.nlm.nih.gov/pubmed/30361442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.RA118.004673 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|